Schedule
-
The Criminal Code
Section
3
CHAPTER 9
-
DANGERS TO THE COMMUNITY
Part 9.1
-
Serious drug offences
History
Pt 9.1 inserted by No 129 of 2005, s 3 and Sch 1 item 1, effective 6 December 2005.
Division 314
-
(Repealed by No 167 of 2012)
History
Div 314 repealed by No 167 of 2012, s 3 and Sch 1 item 19, applicable in relation to offences against Part
9.1
of the
Criminal Code
that are committed on or after 29 May 2013. Div 314 formerly read:
Division 314
-
Drugs, plants, precursors and quantities
SECTION 314.1 Controlled drugs
(1)
The following table lists controlled drugs and sets out quantities:
| Controlled drugs and quantities |
| Controlled drug |
Trafficable |
Marketable |
Commercial |
| |
quantity |
quantity |
quantity |
| |
(grams) |
(grams) |
(kilograms) |
| 1
Amphetamine |
2.0 |
250.0 |
0.75 |
| 1A
Benzylpiperazine (BZP) |
2.0 |
250.0 |
0.75 |
| 2
Cannabis (in any form, including flowering or fruiting tops, leaves, seeds or stalks, but not including Cannabis resin or Cannabis fibre) |
250.0 |
25,000.0 |
125.0 |
| 3
Cannabis resin |
20.0 |
25,000.0 |
125.0 |
| 4
Cocaine |
2.0 |
250.0 |
2.0 |
| 5
Gammabutyrolactone (GBL) |
0.5 |
250.0 |
1.0 |
| 6
4-Hydroxybutanoic acid (GHB) |
0.5 |
250.0 |
1.0 |
| 7
Heroin (diacetylmorphine) |
2.0 |
250.0 |
1.5 |
| 7A
Ketamine |
3.0 |
500.0 |
1.0 |
| 8
Lysergide (LSD) |
0.002 |
0.05 |
0.002 |
| 9
Methamphetamine |
2.0 |
250.0 |
0.75 |
| 9A
Methcathinone |
2.0 |
250.0 |
0.75 |
| 10
3,4-Methylenedioxyamphetamine (MDA) |
0.5 |
100.0 |
0.75 |
| 11
3,4-Methylenedioxymethamphetamine (MDMA) |
0.5 |
100.0 |
0.5 |
| 11A
4-Methylmethcathinone (4-MMC) |
2.0 |
250.0 |
0.75 |
| 12
Opium |
20.0 |
10,000.0 |
20.0 |
| 13
Psilocine |
2.0 |
1,000.0 |
2.0 |
| 14
Psilocybine |
2.0 |
1,000.0 |
2.0 |
| 15
Tetrahydrocannabinol (THC) |
2.0 |
1,000.0 |
5.0 |
History
S 314.1(1) amended by No 24 of 2012, s 3 and Sch 5 items 1
-
4, by inserting table items 1A, 7A, 9A and 11A, effective 4 April 2012.
(2)
A substance is a controlled drug if the substance (the
drug analogue
) is, in relation to a controlled drug listed in subsection (1) (or a stereoisomer, a structural isomer (with the same constituent groups) or an alkaloid of such a controlled drug):
(a)
a stereoisomer; or
(b)
a structural isomer having the same constituent groups; or
(c)
an alkaloid; or
(d)
a structural modification obtained by the addition of one or more of the following groups:
(i)
alkoxy, cyclic diether, acyl, acyloxy, mono-amino or dialkylamino groups with up to 6 carbon atoms in any alkyl residue;
(ii)
alkyl, alkenyl or alkynyl groups with up to 6 carbon atoms in the group, where the group is attached to oxygen (for example, an ester or an ether group), nitrogen, sulphur or carbon;
(iii)
halogen, hydroxy, nitro or amino groups; or
(e)
a structural modification obtained in one or more of the following ways:
(i)
by the replacement of up to 2 carbocyclic or heterocyclic ring structures with different carbocyclic or heterocyclic ring structures;
(ii)
by the addition of hydrogen atoms to one or more unsaturated bonds;
(iii)
by the replacement of one or more of the groups specified in paragraph (d) with another such group or groups;
(iv)
by the conversion of a carboxyl or an ester group into an amide group; or
(f)
otherwise a homologue, analogue, chemical derivative or substance substantially similar in chemical structure;
however obtained, except where the drug analogue is separately listed in subsection (1).
(3)
The trafficable quantity for a drug analogue described in subsection (2) is:
(a)
unless paragraph (b) applies
-
the trafficable quantity set out in the table in subsection (1) for the controlled drug to which the drug analogue relates (whether directly or indirectly); or
(b)
if the drug analogue relates to more than one controlled drug listed in the table in subsection (1)
-
the smallest trafficable quantity set out in the table in subsection (1) for any of those controlled drugs.
(4)
The marketable quantity for a drug analogue described in subsection (2) is:
(a)
unless paragraph (b) applies
-
the marketable quantity set out in the table in subsection (1) for the controlled drug to which the drug analogue relates (whether directly or indirectly); or
(b)
if the drug analogue relates to more than one controlled drug listed in the table in subsection (1)
-
the smallest marketable quantity set out in the table in subsection (1) for any of those controlled drugs.
(5)
The commercial quantity for a drug analogue described in subsection (2) is:
(a)
unless paragraph (b) applies
-
the commercial quantity set out in the table in subsection (1) for the controlled drug to which the drug analogue relates (whether directly or indirectly); or
(b)
if the drug analogue relates to more than one controlled drug listed in the table in subsection (1)
-
the smallest commercial quantity set out in the table in subsection (1) for any of those controlled drugs.
History
S 314.1 inserted by No 129 of 2005, s 3 and Sch 1 item 1, effective 6 December 2005.
SECTION 314.2
SECTION 314.2 Controlled plants
314.2
The following table lists controlled plants and set out quantities:
| Controlled plants and quantities |
| Controlled plant |
Trafficable |
Marketable |
Commercial |
| |
quantity |
quantity |
quantity |
| 1
Any plant of the genus Cannabis |
250 g or 10 plants |
25 kg or 100 plants |
250 kg or 1,000 plants |
History
S 314.2 inserted by No 129 of 2005, s 3 and Sch 1 item 1, effective 6 December 2005.
SECTION 314.3 Controlled precursors
(1)
The following table lists controlled precursors and sets out quantities:
| Controlled precursors and quantities |
| Controlled precursor |
Marketable |
Commercial |
| |
quantity |
quantity |
| |
(grams) |
(kilograms) |
| 1
Ephedrine |
400.0 |
1.2 |
| 2
Ergometrine |
0.15 |
0.006 |
| 3
Ergotamine |
0.25 |
0.01 |
| 4
Isosafrole |
290.0 |
1.45 |
| 5
Lysergic acid |
0.075 |
0.003 |
| 6
3,4-Methylenedioxyphenylacetic acid |
300.0 |
1.5 |
| 7
3,4-Methylenedioxyphenyl-2-propanone |
150.0 |
0.75 |
| 8
Phenylacetic acid |
1,350.0 |
4.05 |
| 8A
Phenylpropanolamine |
400.0 |
1.2 |
| 9
Phenyl-2-propanone |
675.0 |
2.03 |
| 10
Piperonal |
320.0 |
1.6 |
| 11
Pseudoephedrine |
400.0 |
1.2 |
| 12
Safrole |
570.0 |
2.85 |
History
S 314.3(1) amended by No 24 of 2012, s 3 and Sch 5 item 5, by inserting table item 8A, effective 4 April 2012.
(2)
A substance is a controlled precursor if the substance is a salt or ester of a precursor listed in the table in subsection (1).
History
S 314.3 inserted by No 129 of 2005, s 3 and Sch 1 item 1, effective 6 December 2005.
SECTION 314.4 Border controlled drugs
(1)
The following table lists border controlled drugs and sets out quantities:
| Controlled precursors and quantities |
| Controlled precursor |
Marketable |
Commercial |
| |
quantity |
quantity |
| |
(grams) |
(grams) |
| 1
Acetorphine |
2.0 |
2.0 |
| 2
Acetyl-alpha-methylfentanyl |
0.005 |
0.005 |
| 3
Acetylcodeine |
2.0 |
2.0 |
| 4
Acetyldihydrocodeine |
2.0 |
2.0 |
| 5
Acetylmethadol |
2.0 |
2.0 |
| 6
Allylprodine |
2.0 |
2.0 |
| 7
Alphacetylmethadol |
10.0 |
10.0 |
| 8
Alphameprodine |
0.2 |
0.2 |
| 9
Alphamethadol |
0.2 |
0.2 |
| 10
alpha-Methylfentanyl |
0.005 |
0.005 |
| 11
alpha-Methylthiofentanyl |
0.005 |
0.005 |
| 12
Alphaprodine |
25.0 |
25.0 |
| 13
Amphecloral |
2.0 |
2.0 |
| 14
3-(2-Aminopropyl)indole (alpha-methyltryptamine (AMT)) |
2.0 |
2.0 |
| 15
Amphetamine |
2.0 |
0.75 |
| 16
Anileridine |
25.0 |
25.0 |
| 17
Barbiturates |
50.0 |
5.0 |
| 18
Benzethidine |
10.0 |
10.0 |
| 19
Benzoylecgonine |
2.0 |
2.0 |
| 20
Benzylmorphine |
5.0 |
5.0 |
| 20A
Benzylpiperazine (BZP) |
2.0 |
0.75 |
| 21
Betacetylmethadol |
5.0 |
5.0 |
| 22
beta-Hydroxyfentanyl |
0.005 |
0.005 |
| 23
beta-Hydroxy-3-methylfentanyl |
0.005 |
0.005 |
| 24
Betameprodine |
5.0 |
5.0 |
| 25
Betamethadol |
5.0 |
5.0 |
| 26
Betaprodine |
5.0 |
5.0 |
| 27
Bezitramide |
5.0 |
5.0 |
| 28
4-Bromo-2,5-dimethoxy amphetamine |
0.5 |
0.5 |
| 29
Bufotenine |
2.0 |
2.0 |
| 30
Cannabinoids (other than a Cannabinoid of a kind that can be obtained from a plant that is not a Cannabis plant) |
2.0 |
2.0 |
| 31
Cannabis (in any form, including flowering or fruiting tops, leaves, seeds or stalks, but not including Cannabis resin or Cannabis fibre) |
25,000.0 |
100.0 |
| 32
Cannabis resin |
20.0 |
50.0 |
| 33
Chlorophentermine |
2.0 |
2.0 |
| 34
Clonitazene |
5.0 |
5.0 |
| 35
Cocaine |
2.0 |
2.0 |
| 36
Codeine |
10.0 |
10.0 |
| 37
Codeine-N-oxide |
10.0 |
10.0 |
| 38
Codoxime |
10.0 |
10.0 |
| 39
Desomorphine |
2.0 |
2.0 |
| 40
Dexamphetamine |
2.0 |
2.0 |
| 41
Dextromoramide |
2.0 |
2.0 |
| 42
2,5-Dimethoxy-4-n-propylthiophenethylamine (2C-T-7) |
0.5 |
0.5 |
| 43
2,5-Dimethoxy-4-ethylthiophenethylamine (2C-T-2) |
0.5 |
0.5 |
| 44
2,5-Dimethoxy-4-iodophenethylamine (2C-I) |
0.5 |
0.5 |
| 45
Diampromide |
5.0 |
5.0 |
| 46
Diethylpropion |
5.0 |
5.0 |
| 47
Diethylthiambutene |
5.0 |
5.0 |
| 48
N,N-Diethyltryptamine |
2.0 |
2.0 |
| 49
Difenoxin |
2.0 |
2.0 |
| 50
Dihydrocodeine |
10.0 |
10.0 |
| 51
Dihydromorphine |
10.0 |
10.0 |
| 52
Dimenoxadol |
10.0 |
10.0 |
| 53
Dimepheptanol |
10.0 |
10.0 |
| 54
2,5-Dimethoxy-4-methyl amphetamine |
2.0 |
0.75 |
| 55
1-Dimethylamino-1,2-diphenyl ethane |
5.0 |
5.0 |
| 56
Dimethylthiambutene |
20.0 |
20.0 |
| 57
N,N-Dimethyltryptamine |
2.0 |
2.0 |
| 58
Dioxaphetyl butyrate |
2.0 |
2.0 |
| 59
Diphenoxylate |
2.0 |
2.0 |
| 60
Dipipanone |
10.0 |
10.0 |
| 61
Drotebanol |
2.0 |
2.0 |
| 62
Ecgonine |
10.0 |
10.0 |
| 63
Ethchlorvynol |
50.0 |
50.0 |
| 64
Ethinamate |
50.0 |
50.0 |
| 65
Ethylmethylthiambutene |
10.0 |
10.0 |
| 66
Ethylmorphine |
2.0 |
2.0 |
| 67
Etonitazene |
5.0 |
5.0 |
| 68
Etorphine |
5.0 |
5.0 |
| 69
Etoxeridine |
5.0 |
5.0 |
| 70
Fentanyl |
0.005 |
0.005 |
| 71
Furethidine |
1.0 |
1.0 |
| 72
Gammabutyrolactone (GBL) |
2.0 |
1.0 |
| 73
Glutethimide |
50.0 |
50.0 |
| 74
Harmaline |
2.0 |
5.0 |
| 75
Harmine |
2.0 |
5.0 |
| 76
Heroin (diacetylmorphine) |
2.0 |
1.5 |
| 77
Hydrocodone |
2.0 |
2.0 |
| 78
Hydromorphinol |
2.0 |
2.0 |
| 79
Hydromorphone |
2.0 |
2.0 |
| 80
Hydroxyamphetamine |
2.0 |
2.0 |
| 81
4-Hydroxybutanoic acid (GHB) |
2.0 |
1.0 |
| 82
Hydroxypethidine |
5.0 |
5.0 |
| 83
Isomethadone |
2.0 |
2.0 |
| 83A
Ketamine |
3.0 |
1.0 |
| 84
Ketobemidone |
2.0 |
2.0 |
| 85
Levophenacylmorphan |
2.0 |
2.0 |
| 86
Levomethorphan, but not including dextromethorphan |
2.0 |
2.0 |
| 87
Levorphanol, but not including dextrorphan |
1.0 |
1.0 |
| 88
Lysergamide |
0.1 |
0.01 |
| 89
Lysergide (LSD) |
0.002 |
0.002 |
| 90
Meprobamate |
50.0 |
50.0 |
| 91
Mescaline |
7.5 |
7.5 |
| 92
Metazocine |
7.0 |
7.0 |
| 93
Methadone |
2.0 |
2.0 |
| 93A
Methamphetamine |
2.0 |
0.75 |
| 94
Methaqualone |
50.0 |
5.0 |
| 95
Methcathinone |
2.0 |
0.75 |
| 96
Methorphan, but not including dextromethorphan |
2.0 |
2.0 |
| 97
5-Methoxy-alpha-methyltrypt amine (5-MeO-AMT) |
2.0 |
2.0 |
| 98
5-Methoxy-N,N-diisopropyl tryptamine (5-MeO-DiPT) |
2.0 |
2.0 |
| 99
(Repealed by No 24 of 2012) |
|
|
| 100
3,4-Methylenedioxyamphetamine (MDA) |
0.5 |
0.75 |
| 101
3,4-Methylenedioxymethamphet amine (MDMA) |
0.5 |
0.5 |
| 102
Methyldesorphine |
2.0 |
2.0 |
| 103
Methyldihydromorphine |
2.0 |
2.0 |
| 104
3-Methylfentanyl |
0.005 |
0.005 |
| 104A
4-Methylmethcathinone (4-MMC) |
2.0 |
0.75 |
| 105
Methylphenidate |
2.0 |
2.0 |
| 106
1-Methyl-4-phenyl-4-propion oxypiperidine (MPPP) |
2.0 |
2.0 |
| 107
3-Methylthiofentanyl |
0.005 |
0.005 |
| 108
Methyprylon |
50.0 |
50.0 |
| 109
Metopon |
2.0 |
2.0 |
| 110
Monoacetylmorphines |
2.0 |
2.0 |
| 111
Moramide |
2.0 |
2.0 |
| 112
Morphan, but not including dextrorphan |
2.0 |
2.0 |
| 113
Morpheridine |
2.0 |
2.0 |
| 114
Morphine |
2.0 |
1.5 |
| 115
Morphine-N-oxide |
2.0 |
2.0 |
| 116
Myrophine |
20.0 |
20.0 |
| 117
Nicocodine |
2.0 |
2.0 |
| 118
Nicodicodine |
2.0 |
2.0 |
| 119
Nicomorphine |
2.0 |
2.0 |
| 120
Noracymethadol |
2.0 |
2.0 |
| 121
Norcodeine |
2.0 |
2.0 |
| 122
Norlevorphanol |
2.0 |
2.0 |
| 123
Normethadone |
5.0 |
5.0 |
| 124
Normorphine |
20.0 |
20.0 |
| 125
Norpipanone |
10.0 |
10.0 |
| 126
Opium |
20.0 |
20.0 |
| 127
Oxycodone |
5.0 |
5.0 |
| 128
Oxymorphone |
2.0 |
2.0 |
| 129
para-Fluorofentanyl |
0.005 |
0.005 |
| 130
Pentazocine |
20.0 |
20.0 |
| 131
Pethidine |
10.0 |
10.0 |
| 132
Phenadoxone |
10.0 |
10.0 |
| 133
Phenampromide |
10.0 |
10.0 |
| 134
Phenazocine |
1.0 |
1.0 |
| 135
Phencyclidine |
2.0 |
2.0 |
| 136
Phendimetrazine |
5.0 |
5.0 |
| 137
Phenmetrazine |
5.0 |
5.0 |
| 138
Phenomorphan |
5.0 |
5.0 |
| 139
Phenoperidine |
1.0 |
1.0 |
| 140
Phentermine |
5.0 |
5.0 |
| 141
1-Phenylethyl-4-phenyl-4-ace toxypiperidine (PEPAP) |
2.0 |
2.0 |
| 142
Pholcodine |
5.0 |
5.0 |
| 143
Piminodine |
10.0 |
10.0 |
| 144
Pipradrol |
1.0 |
1.0 |
| 145
Piritramide |
1.0 |
1.0 |
| 146
Proheptazine |
1.0 |
1.0 |
| 147
Properidine |
25.0 |
25.0 |
| 148
Propiram |
10.0 |
10.0 |
| 149
Psilocine |
0.1 |
0.1 |
| 150
Psilocybine |
0.1 |
0.1 |
| 151
Tetrahydrocannabinols |
2.0 |
5.0 |
| 152
Thebacon |
2.0 |
2.0 |
| 153
Thebaine |
2.0 |
2.0 |
| 154
Thiofentanyl |
0.005 |
0.005 |
| 155
Trimeperidine |
10.0 |
10.0 |
History
S 314.4(1) amended by No 24 of 2012, s 3 and Sch 5 items 6
-
11, by inserting table items 20A, 83A, 93A and 104A, substituting table item 95 and repealing table item 99, effective 4 April 2012. Table items 95 and 99 formerly read:
| 95
Methcathinone |
|
|
| 99
Methamphetamine |
2.0 |
0.75 |
(2)
A substance is also a border controlled drug if the substance (the
drug analogue
) is, in relation to a border controlled drug listed in subsection (1) (or a stereoisomer, a structural isomer (with the same constituent groups) or an alkaloid of such a border controlled drug):
(a)
a stereoisomer; or
(b)
a structural isomer having the same constituent groups; or
(c)
an alkaloid; or
(d)
a structural modification obtained by the addition of one or more of the following groups:
(i)
alkoxy, cyclic diether, acyl, acyloxy, mono-animo or dialkylamino groups with up to 6 carbon atoms in any alkyl residue;
(ii)
alkyl, alkenyl or alkynyl groups with up to 6 carbon atoms in the group, where the group is attached to oxygen (for example, an ester or an ether group), nitrogen, sulphur or carbon;
(iii)
halogen, hydroxy, nitro or amino groups; or
(e)
a structural modification obtained in one or more of the following ways:
(i)
by the replacement of up to 2 carbocyclic or heterocyclic ring structures with different carbocyclic or heterocyclic ring structures;
(ii)
by the addition of hydrogen atoms to one or more unsaturated bonds;
(iii)
by the replacement of one or more of the groups specified in paragraph (d) with another such group or groups;
(iv)
by the conversion of a carboxyl or an ester group into an amide group; or
(f)
otherwise a homologue, analogue, chemical derivative or substance substantially similar in chemical structure;
however obtained, except where the drug analogue is separately listed in subsection (1).
(3)
The marketable quantity for a drug analogue described in subsection (2) is:
(a)
unless paragraph (b) applies
-
the marketable quantity specified in the table in subsection (1) for the border controlled drug to which the drug analogue relates (whether directly or indirectly); or
(b)
if the drug analogue relates to more than one border controlled drug listed in the table in subsection (1)
-
the smallest marketable quantity specified in the table in subsection (1) for any of those border controlled drugs.
(4)
The commercial quantity for a drug analogue described in subsection (2) is:
(a)
unless paragraph (b) applies
-
the commercial quantity specified in the table in subsection (1) for the border controlled drug to which the drug analogue relates (whether directly or indirectly); or
(b)
if the drug analogue relates to more than one border controlled drug listed in the table in subsection (1)
-
the smallest commercial quantity specified in the table in subsection (1) for any of those border controlled drugs.
History
S 314.4 inserted by No 129 of 2005, s 3 and Sch 1 item 1, effective 6 December 2005.
SECTION 314.5
SECTION 314.5 Border controlled plants
314.5
The following table lists border controlled plants and sets out quantities:
| Border controlled plants and quantities |
| Border controlled precursor |
Marketable |
Commercial |
| |
quantity |
quantity |
| 1
Any plant of the genus Cannabis |
25 kg or 100 plants |
250 kg or 1,000 plants |
| 2
Any plant of the genus Erythroxylon (also known as Erythroxylum) from which cocaine can be extracted either directly or by chemical transformation |
80 kg |
|
| 3
Any plant of the genus Lophophora |
|
|
| 4
Any plant of the species Papaver bracteatum |
10 kg |
|
| 5
Any plant of the species Papaver somniferum |
10 kg |
|
| 6
Any plant of the species Piptagenia peregrine |
|
|
| 7
Any plant of the species Psilocybe |
|
|
History
S 314.5 inserted by No 129 of 2005, s 3 and Sch 1 item 1, effective 6 December 2005.
SECTION 314.6 Border controlled precursors
(1)
The following table lists border controlled precursors and sets out quantities:
| Border controlled precursors and quantities |
| Border controlled precursors |
Marketable |
Commercial |
| |
quantity |
quantity |
| |
(grams) |
(kilograms) |
| 1
N-Acetylanthranilic acid |
|
|
| 2
Any plant of the species Ephedra |
|
|
| 3
Ephedrine |
3.2 |
1.2 |
| 4
Ergometrine |
0.006 |
0.006 |
| 5
Ergotamine |
0.01 |
0.01 |
| 6
Isosafrole |
1.45 |
1.45 |
| 7
Lysergic acid |
0.003 |
0.003 |
| 8
3,4-Methylenedioxyphenyl-2-propanone |
0.75 |
0.75 |
| 9
Phenylacetic acid |
10.8 |
4.05 |
| 10
Phenylpropanolamine |
3.2 |
1.2 |
| 11
Phenyl-2-propanone |
5.4 |
2.03 |
| 12
Piperonal |
1.6 |
1.6 |
| 13
Pseudoephedrine |
3.2 |
1.2 |
| 14
Safrole |
2.85 |
2.85 |
History
S 314.6(1) amended by No 24 of 2012, s 3 and Sch 5 item 12, by substituting table item 10, effective 4 April 2012. Table item 10 formerly read:
(2)
A substance is a border controlled precursor if the substance is a salt or ester of a precursor listed in the table in subsection (1).
(3)
A substance is a border controlled precursor if the substance is a chemical or compound, other than a chemical or compound that is listed in a table in this Division, that, in the manufacture by a chemical process of a chemical or compound referred to in the table in subsection (1), is an immediate precursor of that chemical or compound.
History
S 314.6 inserted by No 129 of 2005, s 3 and Sch 1 item 1, effective 6 December 2005.
Div 314 inserted by No 129 of 2005, s 3 and Sch 1 item 1, effective 6 December 2005.
SECTION 314.1
Controlled drugs
(1)
The following table lists controlled drugs and sets out quantities:
| Controlled drugs and quantities |
| Controlled drug |
Trafficable |
Marketable |
Commercial |
| |
quantity |
quantity |
quantity |
| |
(grams) |
(grams) |
(kilograms) |
| 1
Amphetamine |
2.0 |
250.0 |
0.75 |
| 1A
Benzylpiperazine (BZP) |
2.0 |
250.0 |
0.75 |
| 2
Cannabis (in any form, including flowering or fruiting tops, leaves, seeds or stalks, but not including Cannabis resin or Cannabis fibre) |
250.0 |
25,000.0 |
125.0 |
| 3
Cannabis resin |
20.0 |
25,000.0 |
125.0 |
| 4
Cocaine |
2.0 |
250.0 |
2.0 |
| 5
Gammabutyrolactone (GBL) |
0.5 |
250.0 |
1.0 |
| 6
4-Hydroxybutanoic acid (GHB) |
0.5 |
250.0 |
1.0 |
| 7
Heroin (diacetylmorphine) |
2.0 |
250.0 |
1.5 |
| 7A
Ketamine |
3.0 |
500.0 |
1.0 |
| 8
Lysergide (LSD) |
0.002 |
0.05 |
0.002 |
| 9
Methamphetamine |
2.0 |
250.0 |
0.75 |
| 9A
Methcathinone |
2.0 |
250.0 |
0.75 |
| 10
3,4-Methylenedioxyamphetamine (MDA) |
0.5 |
100.0 |
0.75 |
| 11
3,4-Methylenedioxymethamphetamine (MDMA) |
0.5 |
100.0 |
0.5 |
| 11A
4-Methylmethcathinone (4-MMC) |
2.0 |
250.0 |
0.75 |
| 12
Opium |
20.0 |
10,000.0 |
20.0 |
| 13
Psilocine |
2.0 |
1,000.0 |
2.0 |
| 14
Psilocybine |
2.0 |
1,000.0 |
2.0 |
| 15
Tetrahydrocannabinol (THC) |
2.0 |
1,000.0 |
5.0 |
History
S 314.1(1) amended by No 24 of 2012, s 3 and Sch 5 items 1
-
4, by inserting table items 1A, 7A, 9A and 11A, effective 4 April 2012.
(2)
A substance is a controlled drug if the substance (the
drug analogue
) is, in relation to a controlled drug listed in subsection (1) (or a stereoisomer, a structural isomer (with the same constituent groups) or an alkaloid of such a controlled drug):
(a)
a stereoisomer; or
(b)
a structural isomer having the same constituent groups; or
(c)
an alkaloid; or
(d)
a structural modification obtained by the addition of one or more of the following groups:
(i)
alkoxy, cyclic diether, acyl, acyloxy, mono-amino or dialkylamino groups with up to 6 carbon atoms in any alkyl residue;
(ii)
alkyl, alkenyl or alkynyl groups with up to 6 carbon atoms in the group, where the group is attached to oxygen (for example, an ester or an ether group), nitrogen, sulphur or carbon;
(iii)
halogen, hydroxy, nitro or amino groups; or
(e)
a structural modification obtained in one or more of the following ways:
(i)
by the replacement of up to 2 carbocyclic or heterocyclic ring structures with different carbocyclic or heterocyclic ring structures;
(ii)
by the addition of hydrogen atoms to one or more unsaturated bonds;
(iii)
by the replacement of one or more of the groups specified in paragraph (d) with another such group or groups;
(iv)
by the conversion of a carboxyl or an ester group into an amide group; or
(f)
otherwise a homologue, analogue, chemical derivative or substance substantially similar in chemical structure;
however obtained, except where the drug analogue is separately listed in subsection (1).
(3)
The trafficable quantity for a drug analogue described in subsection (2) is:
(a)
unless paragraph (b) applies
-
the trafficable quantity set out in the table in subsection (1) for the controlled drug to which the drug analogue relates (whether directly or indirectly); or
(b)
if the drug analogue relates to more than one controlled drug listed in the table in subsection (1)
-
the smallest trafficable quantity set out in the table in subsection (1) for any of those controlled drugs.
(4)
The marketable quantity for a drug analogue described in subsection (2) is:
(a)
unless paragraph (b) applies
-
the marketable quantity set out in the table in subsection (1) for the controlled drug to which the drug analogue relates (whether directly or indirectly); or
(b)
if the drug analogue relates to more than one controlled drug listed in the table in subsection (1)
-
the smallest marketable quantity set out in the table in subsection (1) for any of those controlled drugs.
(5)
The commercial quantity for a drug analogue described in subsection (2) is:
(a)
unless paragraph (b) applies
-
the commercial quantity set out in the table in subsection (1) for the controlled drug to which the drug analogue relates (whether directly or indirectly); or
(b)
if the drug analogue relates to more than one controlled drug listed in the table in subsection (1)
-
the smallest commercial quantity set out in the table in subsection (1) for any of those controlled drugs.
History
S 314.1 inserted by No 129 of 2005, s 3 and Sch 1 item 1, effective 6 December 2005.
View history note
Hide history note